Adaptive radiotherapy using a new linear accelerator for cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of the Varian/SHS ETHOS treatment system for online adaptive radiotherapy (ART) in patients with various types of cancer. It aims to dynamically adjust radiation treatment plans on a daily basis to accommodate changes in tumor size or position, utilizing cone beam computed tomography for real-time imaging. The study will assess the feasibility and acceptability of ART across different tumor types and integrate patient-reported outcomes to enhance treatment monitoring. This is an observational study that will gather data over several weeks of therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (\>18 years)
* All tumor entities with an indication for radiotherapy and/or chemoradiotherapy
* Signed informed consent

Exclusion Criteria:

* Pregnancy
* Patients who are not capable of giving consent

Where it's running

• Charité - Universitätsmedizin
  Berlin, Germany Recruiting

Study contacts

• Study coordinator: Goda Kalinauskaite, MD
• Email: goda.kalinauskaite@charite.de
• Phone: +49 30 450 527318

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Investigating HER3-DXd for advanced solid tumors

  This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.

  Recruiting at 92 sites Phase 2 Daiichi Sankyo · Duarte, California and 95 other locations · NCT06172478

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

• Evaluating progastrin levels in cancer patients

  This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.

  Recruiting at 17 sites Hospices Civils de Lyon · Bron and 16 other locations · NCT03787056

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.